
Barbara Coffey
Professor and Chair, Department of Psychiatry and Behavioral Sciences · University of Miami/Jackson Health System
Credentials: · · · · · ·
History
- Present
Department of Psychiatry and Behavioral Sciences · University of Miami/Jackson Health System
- Present
Child and Adolescent Psychiatry Division · University of Miami/Jackson Health System
- Present
UHealth Tourette Center of Excellence · University of Miami/Jackson Health System
1979–1981- 1975–1979
Boston University Medical Campus
1971–1975
Research
The NKI-Rockland Sample: A Model for Accelerating the Pace of Discovery Science in Psychiatry
Frontiers in Neuroscience · 2012 · 631 citations
Systematic review or meta-analysis · American Journal of Psychiatry · 2019 · 318 citations
Systematic review or meta-analysis · Journal of the American Academy of Child & Adolescent Psychiatry · 1998 · Last of 7 authors · 200 citations

21 papers · 9 as a fellow
- DG
18 papers
- JB
17 papers

15 papers · 11 as a fellow

12 papers
- TS
12 papers
- RK
11 papers
- CB
9 papers
Grants
- 2022–2025
Exploring the Role of Neuroactive Steroids in Tourette Syndrome
National Institute of Neurological Disorders and Stroke · R21
PI · $458.9K · Utah State Higher Education System--University of Utah
- 2022–2025
Exploring the Role of Microbiota and Inflammation in Tic Fluctuations
National Institute of Neurological Disorders and Stroke · R21
PI · $435.8K · Utah State Higher Education System--University of Utah
- 2018–2024
7-7-Collaborative Genomic Studies of Tourette Disorder
National Institute of Mental Health · R01
Contact PI · $690.1K · University of Miami School of Medicine
- 2011–2015
8/8-Collaborative Genomic Studies of Tourette Disorder
National Institute of Mental Health · R01
Contact PI · $280K · Icahn School of Medicine at Mount Sinai
Clinical trials
- 2012–2016
Guanfacine in Children With Tic Disorders
Principal investigator · Completed · Phase 4
Yale University
- 2025–2027
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
Site PI · Recruiting · Phase 2
Mirum Pharmaceuticals, Inc.
Expanded Access Program for Treatment With Ecopipam for Tourette's Disorder
Site PI · Available
Emalex Biosciences Inc.
